Evidence map›Paper›PMID 40476686›Full record

ArticleFuture oncology (London, England)2025

Indirect treatment comparisons of momelotinib vs pacritinib safety and anemia outcomes in patients with myelofibrosis.

Lucia Masarova, Srdan Verstovsek, Francesca Palandri, Ruben Mesa, Claire Harrison, Balázs Dobi, Boris Gorsh, Zhaohui Wang, Catherine Ellis, Dwaipayan Patnaik and 2 more

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Future oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Lucia MasarovaDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Srdan VerstovsekDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Francesca PalandriIRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Ruben MesaWake Health, Winston-Salem, NC, USA.
Claire HarrisonGuy's and St Thomas' NHS Foundation Trust, London, UK.
Balázs DobiEvidera, Budapest, Hungary.
Boris GorshGSK plc, Philadelphia, PA, USA.
Zhaohui WangGSK plc, Philadelphia, PA, USA.
Catherine EllisGSK plc, Philadelphia, PA, USA.
Dwaipayan PatnaikGSK plc, Baar, Switzerland.
Tom LiuGSK plc, Philadelphia, PA, USA.
Venediktos KapetanakisEvidera, London, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo perform an indirect treatment comparison of safety and anemia outcomes between the Janus kinase (JAK) inhibitors momelotinib and pacritinib in patients with myelofibrosis.

methodsTreatment-emergent adverse events (AEs) and anemia outcomes were compared in a pooled population of JAK inhibitor - experienced and - naive patients treated with momelotinib (SIMPLIFY-1/SIMPLIFY-2/MOMENTUM) or pacritinib (PERSIST-2/PAC203).

resultsMomelotinib had statistically significantly lower odds and risk for all grades of diarrhea, nausea, peripheral edema, and vomiting as well as grade 3/4 and serious AEs vs pacritinib. Momelotinib-treated patients also had greater odds/possibility of hemoglobin improvement of ≥ 1 g/dL and clinical improvement in hemoglobin.

conclusionsMomelotinib provides a more favorable safety profile and a higher chance for hemoglobin improvement vs pacritinib.

Indexed as

AnemiaBenzamidesBridged-Ring CompoundsJanus Kinase InhibitorsPrimary MyelofibrosisPyrimidinesPyrrolidinesTriazolesAgedAged, 80 and overFemaleHemoglobinsHumansMaleMiddle AgedProtein Kinase Inhibitors11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaeneBenzamidesBridged-Ring CompoundsHemoglobinsJanus Kinase InhibitorsN-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamideProtein Kinase InhibitorsPyrimidinesPyrrolidinesTriazolesindirect treatment comparisonJAK inhibitormomelotinibMyelofibrosispacritinibsafety

Identifiers

PMID40476686
PMCPMC12218468

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.